AbD Serotec and Spinreact Sign Supply Agreement for Antibodies used in Clinical Diagnostic Kits

Jul 08, 2009

Martinsried/Munich, Germany, and Girona, Spain July 19/23, 2009

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its research and diagnostic antibody segment AbD Serotec and Spinreact S.A., a Spanish biotechnology company with more than 30 years of experience in research and manufacturing of clinical diagnostic reagents, have signed a supply agreement. Initially, the agreement covers the use of two antibodies which Spinreact will incorporate in a series of clinical diagnostic kits. AbD Serotec will continuously supply Spinreact with antibody material. Financial details of the agreement were not disclosed.

Dr Josep Puig, Chief Executive Officer of Spinreact, said “Spinreact is delighted to announce this agreement with AbD Serotec – an industry leader in providing tailored antibodies for research and diagnostic applications. The fast turn-around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of development and validation, allowing Spinreact to bring new clinical diagnostic reagents for human diseases to the market in the shortest possible timeframe.”

“Today’s news represents another example of the higher value-added projects that AbD Serotec is increasingly pursuing in line with our strategy to increase our efforts on the diagnostics side of the business,” commented Dieter Feger, Senior Vice President and Head of MorphoSys’s AbD Serotec unit. “We welcome the decision of Spinreact to use AbD Serotec antibodies in its clinical diagnostic reagents. This agreement adds to the growing number of leading diagnostics companies that have chosen to partner with AbD Serotec to bring innovative diagnostic solutions to doctors and patients.”

Following Swedish diagnostic company Phadia AB, Spinreact is the second significant diagnostic company to implement antibodies provided by AbD Serotec into a clinical diagnostic kit.

Meet AbD Serotec at the 2009 AACC Annual Meeting in Chicago, IL, USA July 19th to 23rd at booth No.: 4132.

About MorphoSys:

MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys’s goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world’s largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit www.morphosys.com


Spinreact, S.A. is a Concateno group company and is a leader in Latex reagents and in Haemostasis. We are developing a new project with new latex particles and human antibodies. Spinreact, is a manufacturer for in vitro diagnostic reagents and is producing reagents for Biochemistry, Serology and Immunochemistry. Our introduction in Concateno group of companies has allowed us to provide the latest technology for drugs of abuse detection to our customers. Further information is placed in our website: www.spinreact.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered trademarks of MorphoSys AG

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact MorphoSys:

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications and Investor Relations
Tel: +49 (0) 89 / 899 27-122
Fax: +49 (0) 89 / 899 27-5122

Mario Brkulj
Senior Manager Corporate Communications and Investor Relations
Tel: +49 (0) 89 / 899 27-454
Fax: +49 (0) 89 / 899 27-5454


Indiana University Medical SchoolIndianapolis, INJuly 23
Washington UniversitySaint Louis, MOAugust 6